Thromb Haemost 2003; 90(02): 185-193
DOI: 10.1160/TH03-02-0071
Review Article
Schattauer GmbH

Type II transmembrane serine proteases

Roman Szabo
1   Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, USA
,
Qingyu Wu
2   Berlex Biosciences, Richmond, California, USA
,
Robert B. Dickson
3   Lombardi Cancer Center, Georgetown University Medical Center, Washington, District of Colombia, USA
,
Sarah Netzel-Arnett
4   Vascular Biology Department, Jerome H. Holland Laboratory for the Biomedical Sciences, American Red Cross, Rockville, Maryland, USA
,
Toni M. Antalis
4   Vascular Biology Department, Jerome H. Holland Laboratory for the Biomedical Sciences, American Red Cross, Rockville, Maryland, USA
,
Thomas H. Bugge
1   Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, USA
› Author Affiliations
Further Information

Publication History

Received 03 February 2003

Accepted after revision 28 February 2003

Publication Date:
06 December 2017 (online)

Preview

Summary

The recent availability of human and mouse genome sequences and expressed sequence tag databases facilitated the identification of a large new family of membrane anchored serine proteases, the type II transmembrane serine proteases or TTSPs. Analyses of human inherited disorders and gene targeting studies in mice have revealed that several members of this new protease family have critical functions in development and health. Preliminary studies also suggest that aberrant expression of type II transmembrane serine proteases may be linked to disease progression. The knowledge gathered thus far of the genetics, physiology, and pathology of this interesting new serine protease family will be reviewed here in brief.